879014-17-2

Basic information

• Product Name: 4-broMo-6,7-diMethoxycinnoline
• Synonyms: 4-broMo-6,7-diMethoxycinnoline
• CAS NO: 879014-17-2
• Molecular Formula: C₁₀H₉BrN₂O₂
• Molecular Weight: 269.09466
• Mol File: 879014-17-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 382.3±52.0 °C(Predicted)
• Appearance: /
• Density: 1.544±0.06 g/cm3(Predicted)
• PKA: 0.41±0.10(Predicted)
• CAS DataBase Reference: 4-broMo-6,7-diMethoxycinnoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-6,7-diMethoxycinnoline(879014-17-2)
• EPA Substance Registry System: 4-broMo-6,7-diMethoxycinnoline(879014-17-2)

Safety Data

• Hazardous Substances Data: 879014-17-2(Hazardous Substances Data)

Upstream product

• 4101-30-8 2-amino-4,5-dimethoxyacetophenone 
• 99072-22-7 6,7-dimethoxycinnolin-4-ol 

Downstream Products

• 1057337-37-7 4-(6,7-dimethoxycinnolin-4-yl)benzaldehyde 
• 947694-53-3 4-(4-bromo-1H-indazol-1-yl)-6,7-dimethoxycinnoline 

Relevant articles and documents

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors

We report the discovery of 6,7-dimethoxy-4-(pyridin-3-yl)cinnolines as novel inhibitors of phosphodiesterase 10A (PDE10A). Systematic examination and analyses of structure-activity-relationships resulted in single digit nM potency against PDE10A. X-ray co-crystal structure revealed the mode of binding in the enzyme's catalytic domain and the source of selectivity against other PDEs. High in vivo clearance in rats was addressed with the help of metabolite identification (ID) studies. These findings combined resulted in compound 39, a promising potent inhibitor of PDE10A with good in vivo metabolic stability in rats and efficacy in a rodent behavioral model.

AURORA KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula I {INSERT STRUCTURE HERE} wherein A1-8, D,, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.